India Insulin Drug And Delivery Device Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | > 1.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
India Insulin Drug And Delivery Device Market Analysis
India's Insulin Drug and Delivery Device Market is expected to register a CAGR of more than 1% and reach a value of about USD 2.4 billion over the forecast period.
Diabetes was one of the most prominent risk factors for a severe COVID-19 course. This risk was assumed to be influenced by several diabetes-related variables, including advanced age, hyperglycemia, and underlying illnesses (hypertension, cardiovascular disease, chronic renal disease, and obesity). Diabetes was quickly identified as a risk factor for unfavorable outcomes during the COVID-19 pandemic, making diabetes control or delay more important than ever.
Diabetes mellitus, or diabetes in general, is characterized by excessive blood sugar levels. Type 1 diabetes, also known as insulin-dependent diabetes mellitus, is caused by a complete lack of insulin. Type 2 diabetes mellitus is a disease in which the body either produces insufficient insulin or is unable to utilize the insulin that it does generate. Diabetes type 2 is regarded as a lifestyle disease. Sugary sweets are an integral part of Indian culture, as well as historical customs and religious events. According to an article published in "THE HINDU," one in every six diabetics worldwide comes from India. According to data, the country has an estimated 80 million diabetics, ranking second in the globe. Diabetes affects more than half of Indians at some time in their life, making it a serious public health concern. In rural India, the prevalence of type 2 diabetes is also rising. This pushes the market and boosts the rate of adoption of new and sophisticated technology.
India Insulin Drug And Delivery Device Market Trends
Insulin Devices is having highest volume share in the current year
Despite these difficulties, the market for insulin medications and delivery devices in India is strong since there is no alternative main choice. Several commercial activities have been undertaken to improve insulin affordability. The recent introduction of biosimilar insulin products, as well as the prospect of automated interchangeability between biosimilar insulin and original medicines, may assist lower out-of-pocket expenditures. Insulin pump treatment is a well-known insulin delivery technique for people with type 1 diabetes (T1DM). Pumps are a recognized, time-tested treatment alternative for T1DM patients of all ages, providing near-physiological insulin administration when the pancreas does not make insulin. There are also pump variants with remote controllers that allow parents to suspend or bolus insulin from a distance while their child is playing or eating. When compared to injections, insulin infusion pumps prevent big fluctuations in blood glucose levels, cause less discomfort, and dispense more precisely. The benefits of insulin pumps over traditional delivery systems are projected to drive market growth. The market also benefits significantly from the steady increase in the number of suppliers, R&D activities, technical developments in goods, and the worldwide availability of innovative items. Furthermore, favorable reimbursement situations in wealthy countries, as well as an increase in awareness programs in developing economies, are working in the market's favor.
Insulin delivery device technological developments have developed over time, enabling safer and more precise insulin administration. As a result of the aforementioned reasons, the studied market is expected to increase throughout the analysis period.
Rising diabetes prevalence
In India, Diabetes Population is expected to increase with a CAGR of more than 1% over the forecast period.
Diabetes presently affects more than 80 million people in India and is anticipated to impact 10% of the Indian population by 2027. Obesity, particularly central obesity and increased visceral fat due to inactivity, as well as consumption of high-calorie/high-fat and high-sugar diets, are major risk factors for diabetes in Indians. The country's most popular work culture, which consists of sitting for hours in one position and eating fast food with little or no physical exercise, is a major contributor to diabetes in the working-age population, leading to a significant increase in diabetes cases in India.
According to the International Diabetes Federation (IDF), diabetes accounts for 10% of global health spending in India. According to the Government of India's Ministry of Health and Family Welfare, noncommunicable diseases (NCDs) account for 60% of all fatalities in India. Diabetes, cardiovascular disease, cancer, chronic respiratory disease, and other non-communicable diseases. To prevent and control major NCDs, the National Program for the Prevention and Control of Cancer, diabetic, cardiovascular diseases, and Stroke (NPCDCS) includes medical education, health awareness in schools, and diabetic urban design. Diabetes is a data management condition that demonstrates how real-world health and treatment data collection enables integrated and personalized chronic illness management. Both patients and diabetes care providers use continuously collected metabolic, pharmacological, and lifestyle data when making collaborative treatment decisions. Digital health technology, such as digital health applications, aids in diabetes self-management. Diabetes apps facilitate the adoption of lifestyle modifications for diabetes prevention and treatment, as well as the assessment of blood glucose control quality and insulin dose. Integration of Blood Glucose Monitoring with insulin calculators, automated insulin titration software, and remote coaching are other developments that provide patients with poorly controlled diabetes with the extra support they need to improve critical outcomes, thereby improving market prospects in the coming years.
India Insulin Drug And Delivery Device Industry Overview
The market is highly consolidated, with three major manufacturers holding a global market presence and the remaining manufacturers confined to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have the alliance to develop and commercialize Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.
India Insulin Drug And Delivery Device Market Leaders
Novo Nordisk
Sanofi
Eli Lilly
Medtronics
Roche
*Disclaimer: Major Players sorted in no particular order
India Insulin Drug And Delivery Device Market News
- March 2023: Sanofi (India) announced that it had received marketing authorization for its diabetes drug Soliqua (in a pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO).
- October 2022: To tackle the problem of insulin resistance in type-2 diabetics, Glenmark launched Lobeglitazone in India for the first time. The medicine helps in making body cells more receptive to insulin.
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Insulin Drugs
5.1.1 Basal or Long Acting Insulins
5.1.1.1 Lantus (Insulin Glargine)
5.1.1.2 Levemir (Insulin Detemir)
5.1.1.3 Toujeo (Insulin Glargine)
5.1.1.4 Tresiba (Insulin Degludec)
5.1.1.5 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast Acting Insulins
5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2 Humalog (Insulin Lispro)
5.1.2.3 Apidra (Insulin Glulisine)
5.1.3 Traditional Human Insulins
5.1.3.1 Novolin/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Biosimilar Insulins
5.1.4.1 Insulin Glargine Biosimilars
5.1.4.2 Human Insulin Biosimilars
5.1.5 Insulin combinations
5.1.5.1 NovoMix (Biphasic Insulin Aspart)
5.1.5.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.5.3 Xultophy (Insulin Degludec and Liraglutide)
5.2 Insulin Device
5.2.1 Insulin Pumps
5.2.1.1 Insulin Pump Devices
5.2.1.2 Insulin Pump Reservoirs
5.2.1.3 Insulin Infusion sets
5.2.2 Insulin Pens
5.2.2.1 Cartridges in reusable pens
5.2.2.2 Disposable insulin pens
5.2.3 Insulin Syringes
5.2.4 Insulin Jet Injectors
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population
6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Takeda
7.1.2 Novo Nordisk
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck And Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
India Insulin Drug And Delivery Device Industry Segmentation
Human insulin is a medication of the hormone class. Human insulin is used instead of the insulin that the body normally generates. It aids in the transport of blood sugar to various physiological tissues, where it is utilized as an energy source. It also inhibits the liver from producing extra sugar. India's insulin drug and delivery device market is segmented into type (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins, and biosimilar insulins), device type (insulin pens, insulin pumps, insulin syringes, and jet injectors). The report offers the value (in USD million) and volume (in Units million) for the above segments.
| Insulin Drugs | |||||||
| |||||||
| |||||||
| |||||||
| |||||||
|
| Insulin Device | |||||
| |||||
| |||||
| Insulin Syringes | |||||
| Insulin Jet Injectors |
Frequently Asked Questions
What is the current India Insulin Drug And Delivery Device Market size?
The India Insulin Drug And Delivery Device Market is projected to register a CAGR of greater than 1% during the forecast period (2024-2029)
Who are the key players in India Insulin Drug And Delivery Device Market?
Novo Nordisk, Sanofi, Eli Lilly, Medtronics and Roche are the major companies operating in the India Insulin Drug And Delivery Device Market.
What years does this India Insulin Drug And Delivery Device Market cover?
The report covers the India Insulin Drug And Delivery Device Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the India Insulin Drug And Delivery Device Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
India Insulin Drug And Delivery Device Industry Report
Statistics for the 2024 India Insulin Drug And Delivery Device market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Insulin Drug And Delivery Device analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
